Non Hodgkin Lymphoma Clinical Trial

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Summary

A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.

View Eligibility Criteria

Eligibility Criteria

INCLUSION CRITERIA

Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) who are candidates for HDT-ASCT with one of the following conditioning regimens:

carmustine, etoposide, cytarabine, melphalan (BEAM)
cyclophosphamide, carmustine, etoposide (CBV)
thiotepa, busulphan, cyclophosphamide (TBC)
additional myeloablative chemotherapy-based conditioning regimens may be permitted with the approval of the medical monitor
Adjunct radiation therapy to HDT will be allowed.

Adequate organ function is required, defined as follows:

Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
AST, ALT, and alkaline phosphatase < 3 times the upper limit of normal
Creatinine clearance ≥ 40 ml/min (calculated by Cockcroft Gault)
LVEF ≥ 45% by MUGA or resting echocardiogram
Pulmonary function (FEV1 and corrected DLCO) ≥ 45% predicted
Adequate performance status ECOG ≤1

For female subjects of childbearing potential:

A negative serum or urine pregnancy test at screening.
Subject must be willing to use a recommended method of contraception from the start of the screening period and throughout the study period.

For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception:

- Subject must be willing to use a recommended method of contraception and refrain from sperm donation from the start of conditioning therapy for at least 1 year after completion and discussion with a treating physician.

Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.
Ability to provide written informed consent.

EXCLUSION CRITERIA

History of prior ASCT.
Active malignancy other than the one for which the subject is undergoing HDT-ASCT. (Subjects with cervical carcinoma in situ or localized basal or squamous cell carcinoma treated with definitive surgery are eligible.)
Subjects with a serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics.
Active Human Immunodeficiency Virus (HIV) infection and Acquired Immunodeficiency Syndrome (AIDS).
Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 30 days or longer after chemotherapy treatment discontinuation if required by prescribing information for chemotherapy agents received during the study.
Subjects who have known hypersensitivity reactions to bovine (cow) proteins or documented allergy to DMSO.
Subject has other conditions that in the opinion of the investigator would place the subject at increased risk for toxicity by participation in the study.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

42

Study ID:

NCT03925935

Recruitment Status:

Completed

Sponsor:

Angiocrine Bioscience

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States
UC Davis Comprehensive Cancer Center
Sacramento California, 95817, United States
UC San Diego Moores Cancer Center
San Diego California, 92093, United States
The University of California San Francisco
San Francisco California, 94117, United States
University of Michigan
Ann Arbor Michigan, 48109, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Vanderbilt-Ingram Cancer Center
Nashville Tennessee, 37203, United States
MD Anderson
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

42

Study ID:

NCT03925935

Recruitment Status:

Completed

Sponsor:


Angiocrine Bioscience

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider